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Abstract
Background: The Wnt/𝛽-catenin pathway plays a central role in the pathogenesis of most hepa-
toblastomas (HBs), that is, up to 60–80% carry activating CTNNB1 mutations. HBs can however
also be the first manifestation of familial adenomatous polyposis (FAP). As this is a severe disease,
it is important for the patient and related family members to firmly exclude FAP at an early stage.
Current diagnosis largely depends onAPC germlinemutation detection on genomicDNA,which is
associated with 10–20% false-negative results. Here, we establish and validate a tissue-based 𝛽-
catenin gene and immunohistochemical analysis, which complements germline mutation screen-
ing to exclude the diagnosis of FAP amongHB patients.
Methods: Tumor tissues of 18 HB patients, including three FAP cases were subjected to CTNNB1
exon 3 mutational analysis and immunohistochemistry comparing staining patterns for total and
exon 3 specific 𝛽-catenin antibodies.
Results: Our novel tissue-based method reliably identified all three FAP patients. Their tumors
were characterized by a wild-type exon 3 sequence and a comparable nuclear staining for both
antibodies. In contrast, the non-FAP tumors carriedmissenseCTNNB1mutations combinedwith a
clearly reduced staining for the exon 3 antibody, or complete loss of staining in case of lesionswith
exon 3 deletions.
Conclusion:We have successfully established and validated a novel ß-catenin gene and immuno-
histochemical diagnostic method, which, when combined with routine germline DNA testing,
allows the exclusion of the diagnosis of FAP amongHB patients.
K EYWORDS
APC, CTNNB1, familial adenomatous polyposis (FAP), genetic counseling, hepatoblastoma,
Wnt/𝛽-catenin signaling
1 INTRODUCTION
Hepatoblastoma (HB) is the most common pediatric liver malig-
nancy with an estimated incidence of 1 per 100,000 children,
mainly affecting children during their first 3 years of life.1,2 HBs
Abbreviations: BWS, Beckwith–Wiedemann syndrome; FAP, familial adenomatous polyposis; FFPE, formalin-fixed paraffin-embedded; HB, hepatoblastoma; HCA, hepatocellular adenoma; HCC,
hepatocellular carcinoma; IHC, immunohistochemistry; LFS, Li–Fraumeni Syndrome; NF1, neurofibromatosis type 1; S/T, serine/threonine
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are believed to originate from hepatic progenitor cells that acquire
malignant transformation during embryogenesis. Histologically
they show similarity to immature hepatocytes of the develop-
ing liver.3,4 Most HBs are believed to be of sporadic nature, but
about 10–20% have been associated with genetic defects such as
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Beckwith–Wiedemann syndrome (BWS) or familial adenomatous
polyposis (FAP).2,5,6
The Wnt/𝛽-catenin signaling pathway is recognized as having a
central role in the pathogenesis of HBs.4 The 𝛽-catenin protein is
a key effector of the pathway, affecting cellular decisions such as
stem cell maintenance and cell proliferation through modulating the
expression of specific target genes. In normal cells, 𝛽-catenin is
involved both in cell adhesion, when located at the cell membrane,
and in transcriptional regulation, when present in the nucleus. In the
absence of upstream Wnt signaling, 𝛽-catenin is phosphorylated at
N-terminal serine/threonine (S/T) residues by a multiprotein complex
consisting of the adenomatous polyposis coli (APC) tumor suppressor,
scaffold proteins AXIN1, AXIN2, and AMER1, and the kinases GSK3
and CK1𝛼.7–11 Phosphorylated 𝛽-catenin is then ubiquitinated, lead-
ing to its proteasomal degradation.When cells are exposed toWnt lig-
ands, this 𝛽-catenin breakdown complex is temporarily inhibited, lead-
ing to the stabilization of 𝛽-catenin. As a result, it translocates into
the nucleus and associates with members of the TCF/LEF family of
transcription factors, thus regulating the expression of specific down-
streamWnt/𝛽-catenin target genes.
In several tumor types, this pathway is constitutively activated due
to "loss of function" mutations of the APC, AXIN1, or AXIN2 genes
leading to inefficient 𝛽-catenin degradation and its intracellular sta-
bilization. Other tumors carry oncogenic 𝛽-catenin (CTNNB1) muta-
tions within exon 3 at the N-terminal phosphorylation residues, mak-
ing the protein more resistant to proteolytic degradation. Important
for our study, disease-causingmutations in theAPC andCTNNB1 genes
have been shown to occur in a mutually exclusive manner in all tumor
types studied so far.12 These mutations lead to aberrant stabiliza-
tion of 𝛽-catenin, which constitutively activates downstream Wnt/𝛽-
catenin target genes and triggers a genetic program resulting in tumor
formation.
HBs are characterized by a high proportion (60–80%) of activating
mutations within the CTNNB1 gene, either by point mutation or dele-
tions encompassing exon 3.13–22 The deletions represent more than
60% of the somatic CTNNB1 mutations and vary in size from small
intra-exonic deletions to larger ones extending up to part of exon 2 or
4. All of them have in common that they result in in-frame deletions
leading tomutant 𝛽-catenin that is resistant to degradation.
Somatic APCmutations have been rarely reported in HBs.14,16,17,23
However, FAP patients carrying a germline APCmutation present with
a 750–7500-fold increased risk of HB development in comparison
to the general population.2,24–27 FAP is a hereditary predisposition
to develop hundreds to thousands of colorectal polyps ultimately
leading to colorectal cancer. Untreated, the risk of colorectal cancer
in FAP patients approaches 100%. The average age when colorectal
polyps are detected is about 15 years.28 Colonoscopy and surgery in
adolescence prevent colorectal cancer formation in FAP. When FAP
is diagnosed in time, health benefits and increased life expectancy
can be achieved. Importantly, in children HB can be the first mani-
festation of FAP within a family, especially given the high proportion
(10–25%) of de novo germline mutations occurring in the APC
gene.29–31 This is of importance for the management of the child
and its possible future offspring, but it might also have implications
for yet asymptomatic parents and siblings. For this reason, it has
been advocated that all HB patients with unknown family history
should be referred for APC germline mutation detection,6,32–34 using
a combination of currently available methods, such as next-generation
or Sanger sequencing, and multiplex ligation-dependent probe
amplification (MLPA). These methods will uncover up to 80–90% of
disease-causing APC mutations,35,36 but inherent to any diagnostic
method will lead to false-negative results. Examples include complex
insertions and deletions, chromosomal translocations, or instances in
which the patient is a low-mosaic carrier of the APC mutation.37,38
Moreover, sequence analysis will identify genetic variants with
uncertain disease-causing relevance. Given the severity of the FAP
syndrome, a thorough exclusion of carrier status is highly desirable.
Here, we establish and validate a tissue-based 𝛽-catenin gene and
immunohistochemical analysis, which complements the germline
mutation screening to exclude the diagnosis of FAP among HB
patients.We also discuss options regarding how it can be implemented
in current clinical practice.
2 MATERIALS AND METHODS
2.1 Patients
From the period 1995–2013, in total 23 pediatric liver tumors were
available for analysis from the pathology archive of the Erasmus MC.
Tissueswereobtained fromthe initial operativeprocedureandembed-
ded in paraffin after formalin fixation. The medical records and fam-
ily history of patientswere analyzed. Patient and tumor characteristics
are provided in Table 1. All samples were revised by a GI-pathologist
(MD) according to a recently proposed consensus classification for
pediatric liver tumors.39
2.2 Immunohistochemistry (IHC)
Immunohistochemical analyses for total 𝛽-catenin (1:200, clone-
14, BD-Transduction Laboratories) and nonphosphorylated
Ser33/37/Thr41 𝛽-catenin (1:400, #8814, Cell Signaling Technol-
ogy) were performed in an automated stainer (Benchmark-Ultra,
Ventana Medical Systems, Tucson, AZ). Sections were deparaffinized
and pretreated with standard cell conditioning 1 solution (CC1) at
100◦C for 64min, followed by incubationwith the specified antibodies
at 37◦C for 60 min. The antibodies were visualized with the OptiView
IHCDABDetection Kit.
2.3 Tumor DNA and RNA isolation and CTNNB1
mutation analysis
Tumor DNA was extracted by microdissection from formalin-fixed
paraffin-embedded (FFPE) tissue fragments using proteinase-K and
5% Chelex R©-100 Chelating Resin (BioRAD, #1432832), as previously
described.40 Sequence analysis of CTNNB1 exon 3 was performed by
bidirectional sequencing of PCR-amplified fragments usingM13-tailed
forward and reverse primers (Supplementary Material S1). To test for
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TABLE 1 Patient and tumor characteristics
Sample Gender Age (years) HB/HCC Pathology
Known genetic
predisposition
HB-4 F 5.5 HB Epithelial (too few tumor cells for
proper evaluation)
Familial adenomatous
polyposis
HB-6 M 0, 6 HB Epithelial mixed
HB-7 M 2, 1 HB Epithelial fetal
HB-8 M 5, 9 HCC Classic
HB-11 F 1.2 HB Epithelial mixed
HB-13 F 0.5 HB Epithelial mixed
HB-14 M 3.5 HB Epithelial fetal Familial adenomatous
polyposis
HB-15 F 9.7 HCC Classic Belonging to Li–Fraumeni
family (TP53)
HB-16 F 15.8 HCC Fibrolamellar
HB-17 M 9.7 HB Epithelial fetal with lowmitotic
activity
HB-18 F 11.4 HCC Fibrolamellar
HB-19 F 1.7 HB Epithelial fetal with lowmitotic
activity
Hypomethylation of LIT1 (no
signs of BWS)
HB-20 M 1, 1 HB Mixed epithelial-mesenchymal,
no teratoid
See notea
HB-21 M 0.8 HB Epithelial mixed
HB-22 M 1.0 HB Epithelial mixed
HB-23 M 9.4 HB Epithelial fetal
HB-24 M 1.8 HB Epithelial fetal, mitotically active
HB-25 F 16.3 HCA See notea
HB-27 F 7.3 HB Epithelial pleomorphic
HB-28 F 1.1 HB Mixed epithelial-mesenchymal,
teratoid
HB-29 M 1.6 HB Mixed epithelial-mesenchymal,
teratoid
Familial adenomatous
polyposis
HB-30 F 0.8 HB Mixed epithelial-mesenchymal
HB-32 F 1.1 HB Mixed epithelial-mesenchymal,
no teratoid
Neurofibromatosis type 1
HCA, hepatocellular adenoma; HB, hepatoblastoma; HCC, hepatocellular carcinoma.
aSuspicion of syndromic condition based on additional (congenital) abnormalities.
genomic deletions of CTNNB1 exon 3, two independent PCRs were
performed using primers located within exon 2 and exon 4. Details of
the PCR and sequencing reactions and RNA isolation are provided in
SupplementaryMaterial S1.
2.4 Cell lines
Short Tandem Repeat-verified cell lines used in this study were
cultured as previously described.41 Preparation of paraffin-
embedded cell line blocks is described in Supplementary
Material S1.
2.5 Generation of 𝜷-catenin variant expression
vectors and transfection
Expression vectors for N-terminal FLAG-tagged 𝛽-catenin variants
were generated using the pcDNA-5′UT-FLAG vector as basis (kindly
provided by Dr. Veronique Lefebvre, Lerner Research Institute, Cleve-
land OH, USA). Wild-type, S33Y and exon 3 deleted variants of human
CTNNB1 were cloned using the Gibson assembly method (NEB). The
G34V, S37F, T41A, and S45P variants were generated by Q5 R© site-
directedmutagenesis (NEB), using thewild-type cloneasbasis. Primers
are available upon request. All plasmids were fully sequence verified.
Next, HEK-293 cells seeded in 6-well plates were transiently trans-
fected with Fugene-HD (Promega) using 1 𝜇g of plasmid DNA. After
2 days, cells were lysed in Laemmli sample buffer with 0.1 M DTT and
heated for 5–10min at 95˚C.
2.6 Western blot assay
The western blot assay and quantification for the FLAG-tag, total,
and nonphosphorylated Ser33/37/Thr41 𝛽-catenin were performed
basically as previously described, using all antibodies at a 1:1000
dilution.41
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3 RESULTS
3.1 Patient and tumor characteristics
In total, 23 pediatric liver tumors were included in the study (Table 1),
of which 18 were HBs, four hepatocellular carcinomas (HCC), and one
hepatocellular adenoma (HCA). In accordancewith literature,mostHB
patients were diagnosed during their first 3 years of life. The youngest
age at diagnosis was 0.5 years, whereas the oldest patient was 9.7
years old. HB patients HB-4, HB-14, and HB-29 had been diagnosed
with FAP previously. The HCC detected in HB-15 was diagnosed in a
child belonging to a Li–Fraumeni family (LFS), i.e. TP53 germline muta-
tion, whereasHB-32was observed in a patientwith neurofibromatosis
type 1 (NF1). Hypomethylation of LIT1 was reported for patient HB-
19, although no other signs of BWSwere observed.
3.2 IHC for total 𝜷-catenin
IHC for 𝛽-catenin showed nuclear accumulation of 𝛽-catenin in one
HCC (HB-8), while in the remaining three HCCs and the HCA an exclu-
sive membranous pattern was observed (Figure 1). All HBs showed
evidence of nuclear staining, including the ones derived from the FAP
patients. No nuclear 𝛽-catenin was detected in normal pre-existing
hepatocytes.
3.3 CTNNB1mutation analysis
Sequence analysis of exon 3 of CTNNB1 succeeded in 22/23 tumors. In
8/18 HBs point mutations were detected within or in close proximity
to the region encoding the S/T residues required for proteolytic break-
down of 𝛽-catenin (Figure 1). As expected, no mutation was detected
in all three FAP-derivedHBs and in theHCC andHCA sampleswithout
nuclear staining. Also nomutation was detected within the single HCC
with nuclear accumulation of 𝛽-catenin.
HBs are however characterized by a high proportion of genomic
deletions partially or completely encompassing exon 3,13–21 most of
which will be missed by the regular exon 3 sequence analysis. There-
fore, we attempted two genomic PCRs onDNA isolated from the FFPE
samples, using a common forward primer in exon 2 and two reverse
primers, respectively at the 5′- and 3′-side of exon 4. The latter can
detect the reported deletions extending up to the middle of exon
4.13–21 Specific PCR products were detected only in three HB sam-
ples identifying two genomic deletions, both predicted to result in the
loss of critical N-terminal phosphorylation sites (HB-30 and HB-32 in
Figure 1). For the remainder of the samples the FFPE-isolated DNA
quality was apparently of insufficient quality to generate PCR prod-
ucts with the deletion primers, meaning that no judgment can bemade
about a possible deletion. In summary, the DNA analysis identified 10
somatic CTNNB1 mutations, all in HBs showing nuclear accumulation
of 𝛽-catenin.
Sample
HB or
HCC
genec 
predisposion
Nucleode change detected
in genomic DNA
RNA
alteraon
Amino Acid
alteraon C-ter β-cat IHC
S33/37/T41 β-cat 
IHC
HB-15 HCC LFS None Membrane only Membrane only
HB-16 HCC None Membrane only Membrane only
HB-18 HCC None Membrane only Membrane only
HB-25 HCA None Membrane only Membrane only
HB-4 HB FAP p.Q1062* None Nuclear Nuclear
HB-14 HB FAP p.R1114* none Nuclear Nuclear
HB-29 HB FAP p.Q1062* None Nuclear Nuclear
HB-6 HB c.97T>C p.S33P Nuclear Nuclear
HB-17 HB c.86C>T + c.94G>T p.S29F + p.D32Y Nuclear Moderate Nuclear
HB-22 HB c.94G>A p.D32S Nuclear Nuclear
HB-7 HB c.101G>T p.G34V Nuclear Faintly nuclear
HB-13 HB c.101G>T p.G34V Patchy nuclear Faintly nuclear
HB-20 HB c.101G>T p.G34V Nuclear Faintly nuclear
HB-21 HB c.101G>T p.G34V Nuclear Faintly nuclear
HB-28 HB c.121A>G p.T41A Nuclear Patchy nuclear
HB-8 HCC None r.14_241del p.A5_A80del Nuclear Negave
HB-11 HB Not analyzable r.14_241del p.A5_A80del Nuclear Negave
HB-19 HB LIT1 None ±215 bp del p.? Nuclear Negave
HB-23 HB None Nuclear Membrane only
HB-24 HB None r.14_241del p.A5_A80del Nuclear Negave
HB-27 HB None Nuclear Membrane only
HB-30 HB c.98_238del r.98_238del p.G34_A80del Nuclear Negave
HB-32 HB NF1 c.14-202_241+69del r.14_241del p.A5_A80del Nuclear Negave
F IGURE 1 CTNNB1 mutational status and 𝛽-catenin IHC pattern of pediatric liver cancers. At large, four different staining patterns were
observed using the C-terminal and S33/37/T43 𝛽-catenin antibodies. Combined with the genomic mutation analysis, the most likely 𝛽-catenin-
related mechanism contributing to tumor formation is color-coded as follows: Grey = no evidence of mutations leading to 𝛽-catenin activation.
Green=APCmutation or 𝛽-catenin D32/S33 amino acid alterations. Blue= 𝛽-catenin G34 amino acid alteration. Red= 𝛽-catenin exon 3 deletion.
“Nuclear” means a combination of nuclear, cytoplasmic, and membranous staining. “Negative” means no staining visible in tumor cells. HCA, hepa-
tocellular adenoma; HB, hepatoblastoma; HCC, hepatocellular carcinoma; FAP, familial adenomatous polyposis; LFS, Li–Fraumeni syndrome; LIT1,
LIT1 hypomethylation; NF1, neurofibromatosis type-1; IHC, immunohistochemistry
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F IGURE 2 Western blot validation of the nonphospho S33/37/T41 𝛽-catenin antibody. (A) Western blot analysis of one APC mutant and eight
𝛽-catenin mutant cell lines using a C-terminal 𝛽-catenin antibody (upper lanes) in comparison with one raised against a peptide corresponding to
residues surrounding S37 (lower lanes). Amino acid alterations and zygosity status are depicted on top. Name of cell line is in brackets. Deletion
of exon 3 and alterations of S37 and T41 abrogate binding. Reduced signal for S33 and G34 variants suggests lowered affinity, although residual
binding to remaining wild-type protein cannot be formally excluded. S45 changes are largely unaffected. Proportional binding of the S33/37/T41
antibody is shown on the right with the ratio of the APC-mutant SW480 cell line set arbitrarily to one. (B) Transient expression of FLAG-tagged
wild-type and S/T mutant 𝛽-catenin variants shows that S33Y 𝛽-catenin can still be recognized by the S33/37/T41 antibody. The G34V variant
shows a±40% reduced signal intensity. The other variants confirm the cell line analysis. Theweaker bandwith lowermolecular weight visible in all
lanes is the endogenous 𝛽-catenin protein produced byHEK-293 cells. Proportional binding of the S33/37/T41 antibody is shown on the right with
the ratio of the wild-type protein set arbitrarily to one
3.4 Immunohistochemical identification of
𝜷-catenin alterations
Given the poor quality of DNA extracted from FFPE material, we
sought an alternative method to identify samples with genomic
CTNNB1deletions. All thesemutations generatemutant 𝛽-catenin pro-
teins that are more resistant to proteolytic breakdown. Hence, the
great majority of 𝛽-catenin protein present within a CTNNB1 mutant
cell is represented by the mutant protein. This will especially be the
case for the nuclear compartment as most of the wild-type protein
is prevented from entering the nucleus through degradation by the
APC/AXIN breakdown complex. We hypothesized that an immuno-
histochemical analysis using a 𝛽-catenin antibody specifically recog-
nizing the N-terminal S/T residues could distinguish between APC-
and 𝛽-catenin mutant tumors. In APC-mutant tumors, wild-type 𝛽-
catenin accumulates in the nucleus that can still be detected by such
an antibody,whereas (partial) deletionormutationof the 𝛽-catenin S/T
residues would prevent detection.
To validate this approach, we first tested a panel of cell lines
with known CTNNB1mutations using a C-terminal 𝛽-catenin antibody
in comparison with one raised against a peptide corresponding to
residues surrounding S37. Western blot analysis using the C-terminal
antibody robustly demonstrated 𝛽-catenin in all cell lines, including
the shortened mutant product present in HepG2 cells (Figure 2A).
The nonphospho S33/37/T41 antibody readily detected the wild-
type 𝛽-catenin present in the APC-mutant line SW480. Also the S45
mutant 𝛽-catenin present in HCT116 and LS174T was demonstrated
at high intensity compared with the C-terminal antibody. In contrast,
the exon 3 deleted product of HepG2 and S37/T41 alterations com-
pletely abrogated detection, while S33 and G34 alterations resulted
in reduced detection. The latter may represent binding to wild-type
𝛽-catenin present in these cells and/or retained affinity for the mutant
protein.
To investigate residual binding affinity for mutant 𝛽-catenin by
the S33/37/T41 antibody, we transiently expressed N-terminal FLAG-
tagged 𝛽-catenin variants in HEK-293 cells (Figure 2B). Deletion of
exon 3, and S37F/T41A alterations completely abrogated binding.
In contrast, the S33Y variant was identified at comparable levels
to the wild-type protein, while the G34V variant is detected with
±40%reduced signal intensity. In conclusion, the S33/37/T41antibody
retains affinity for S33/G34 alterations when present in denatured
form on western blot, while S37/T41 changes and deletion of exon 3
prevent its binding.
Next, we evaluated this antibody for immunohistochemical pur-
poses using paraffin blocks containing formalin-fixed 𝛽-cateninmutant
cell lines. In line with the western blot data, S45 mutant HCT116 and
LS174T showed a comparable staining pattern for both antibodies
(Figure 3). In strong contrast, all other 𝛽-catenin mutant lines showed
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F IGURE 3 Immunohistochemical validation of the nonphospho S33/37/T41 𝛽-catenin antibody. Formalin-fixed and paraffin-
embedded cell pellets of the 𝛽-catenin mutant cell lines were stained with the C-terminal (top rows) and S33/37/T41 (bottom rows)
𝛽-catenin antibodies. Staining patterns are largely in line with western blot analysis with the exception of the relatively weak staining pat-
tern observed for the G34V protein present in Huh6. HepG2 shows an exclusive membranous staining with the S33/37/T41 antibody, most likely
reflecting the remaining wild-type protein. Both S33 mutant cell lines retain some nuclear detection, albeit slightly reduced. S45 variant cell lines
show identical staining patterns with both antibodies. Original magnification 400×
a clearly reduced overall staining using the S33/37/T41 antibody. The
S37C and T41A mutant lines are completely negative. In the S33
mutant lines SW48 and SW1573 nuclear staining can be observed
in some cells, although with reduced intensity. The exon 3 deletion
mutant HepG2 line showed an exclusive membranous staining, most
likely resulting from detection of the remaining wild-type protein.
Also in the G34V mutant Huh6 line no obvious nuclear staining was
observed. Surprisingly, IHC staining of this variant ismuchweaker than
anticipated from the western blot analysis, most likely resulting from
reducedantibodyaffinitywhenpresent in its “native” form inFFPEsec-
tions and/or partial phosphorylation of S37/T41 residues. In conclu-
sion, the S33/37/T41 𝛽-catenin antibody can reliably identify the cell
lineswith exon3CTNNB1mutations,with theexceptionof S33andS45
alterations.
Next, the S33/37/T41 antibody was applied to the tumor sections
and compared with that of total 𝛽-catenin (Figure 4, Supplementary
Figure S1). At large, four different staining patterns were observed.
The tumors with exclusively membranous 𝛽-catenin were stained in
an identical fashion with the S33/37/T41 antibody (Figure 4A and
4B, Supplementary Figure S1). Importantly, all three FAP-associated
lesions showed basically identical staining patterns with both antibod-
ies as well, that is, a high proportion of tumor cells showing evidence
of nuclear accumulation (Figure 4C and 4D, Supplementary Figure S1).
This pattern was also observed in lesions with D32 and S33 muta-
tions, albeit with slightly lower intensity for the S33/37/T41 antibody
(Figure 4E and 4F, Supplementary Figure S1). The third pattern is
observed in HBs with G34V mutation. These showed a strongly
reduced overall staining using the S33/37/T41 antibody. However,
occasionally tumor cells with nuclear staining can be clearly observed,
especially in regions with heavy staining for total 𝛽-catenin (Figure 4G
and 4H, Supplementary Figure S1). This pattern was also observed in
HB-28, the only lesion with a T41 mutation, in which a heavy over-
all 𝛽-catenin staining is accompanied by occasional nuclear-positive
cells using the S33/37/T41 antibody (Supplementary Figure S1). As
the T41A alteration cannot be detected by this latter antibody, the
nuclear staining most likely results from wild-type protein induced to
enter the nucleus. Lastly, in both HBs with proven genomic exon 3
deletions virtually no tumor cell staining was detectable (Figure 4I and
4J, Supplementary Figure S1). A similar pattern was also identified in
six additional samples with no identifiable point mutation, suggest-
ing that, in total, seven out of 18 HB samples and one HCC sample
carry genomic exon 3 deletions. In two of these samples, some residual
membranous staining was visible (HB-23 and HB-27, Supplementary
Figure S1).
3.5 Confirmation of exon 3 deletion by RT-PCR
To confirm that these latter samples indeed express mutant CTNNB1
mRNA (partially) lacking exon 3, we performed RT-PCR on RNA iso-
lated from paraffin sections. Successful RNA isolation was possible in
six samples. In four out of six samples, a 127 bp product was observed
indicative of a complete absence of exon 3 (Figure 5). In sample HB-
30 a shortened 214 bp product was observed, which, after sequencing,
was confirmed to carry the same intra-exonic 141 bp deletion already
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F IGURE 4 Immunohistochemical identification of 𝛽-catenin alter-
ations in tumor samples. FFPE sections of pediatric liver tumors were
stained with the C-terminal (left column) and S33/37/T41 (right col-
umn) 𝛽-catenin antibodies. (A,B) Comparable membranous staining in
the fibrolamellar hepatocellular carcinoma (HB-18) with no evidence
of 𝛽-catenin mutation or activation. (C,D) HB-29 derived from a FAP
patient shows identical nuclear and cytoplasmic accumulation of wild-
type 𝛽-catenin using both antibodies. (E,F) In sample HB-6 a p.S33P
mutation was detected, which shows nuclear staining with both anti-
bodies, albeit slightly weaker using the S33/37/T41 antibody. (G,H)
Sample HB-20 carrying a p.G34V mutation shows clear nuclear 𝛽-
catenin accumulation in tumor sections. Staining with the S33/37/T41
antibody is strongly reduced or entirely lost in tumor cells, while nor-
mal structures on the left are stained in an identical fashion. (I–L) The
strong nuclear and cytoplasmic staining of sampleHB-30with genomic
deletion of exon 3 is completely lost using the S33/37/T41 antibody.
Original magnification 200×
observed during the genomic DNA analysis. Sample HB-19 showed a
shortened reproducible product of about 140 bp, indicating that an
approximate 215 bp deletion is present in the cDNA. In conclusion, all
six samples with negative S33/37/T41 𝛽-catenin nuclear staining and
absence of exon 3 point mutation showed evidence of (partial) exon 3
deletion on RNA level.
Overall, our combined IHC, RNA, and DNA analysis shows that all
18 HBs are characterized by increased 𝛽-catenin signaling. In three
samples, the underlying cause is a germline APC mutation, while acti-
vating CTNNB1 point mutations are identified in eight cases. For
another five HB cases, we provide evidence that they carry genomic
F IGURE 5 Confirmation of exon 3 deletion by RT-PCR. RNA was
isolated from six HBs with immunohistochemical evidence of (partial)
exon 3 loss, and subjected to RT-PCR using primers in exon 2 and 4. In
four out of six samples, a 127 bp product was observed indicative of a
complete absence of exon 3 (HB-8, HB-11, HB-24, and HB-32). Sam-
ple HB-19 showed a reproducible shortened product of approximately
140 bp (*). In sample HB-30, the intra-exonic 141 bp genomic deletion
was confirmed at RNA level. Positive control is RNA isolated from nor-
mal tissue
exon 3 deletions; this is also highly suggestive for the remaining two
cases based on their IHC staining pattern (HB-23 andHB-27).
4 DISCUSSION
Most HBs are believed to be of sporadic nature, but about 10–
20% have been associated with genetic defects such as Beckwith–
Wiedemann syndrome or FAP.2,5,6 For this reason, it has been advo-
cated that all HB patients with unknown family history should be
referred for genetic counseling.6 Among the genetic syndromes asso-
ciated with HB development, FAP is one of the most common with
an estimated frequency between 5 and 10%.2,16 As this is a severe
disease, it is important for the patient and also for yet asymptomatic
family members to determine their carrier status at an early stage.
Especially a firm exclusion of an underlyingAPC germlinemutationwill
prevent theunexpected emergenceof polyposis or colorectal cancer at
a later stage. Current diagnosis largely depends onAPC germlinemuta-
tion detection on genomicDNA, but inherent to any diagnosticmethod
this will occasionally lead to false-negative results. In case of classi-
cal polyposis phenotypes, the APC mutation detection rate is around
80–90%,35,36 meaning that a possible 10–20% of FAP patients may be
missed by routine genetic testing. This leads to the highly undesired
scenario in which apparent APC mutation negative patients develop
polyposis later. For this reason, Aretz et al. proposed that all APC-
negative HB patients undergo colonoscopy around age 15 and one at
age 25, to also offer parents the option to undergo colonoscopy.2 The
downside of this approach is that many genuine APC-negative indi-
viduals will be exposed to unneeded medical investigations associated
with anxiety and considerable costs. Here, we establish and validate
a tissue-based 𝛽-catenin gene and immunohistochemical analysis that
complements the germline mutation screening to exclude the diagno-
sis of FAP among HB patients. Following successful confirmation in an
independent series, its application will lead to a near-complete exclu-
sion of FAP amongHB patients.
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Our method is based on the observation that tumor-driving
CTNNB1 and APCmutations occur in a mutually exclusive nature in all
tumor types studied so far.12 As such, the identification of a somatic
activating CTNNB1mutation in an HB patient directly reduces the risk
of carrying a germline APC mutation to that of the general popula-
tion. By combining mutational analysis of CTNNB1 exon 3 and IHC
comparing staining patterns for total and S33/37/T41 𝛽-catenin, we
could reliably identify all three FAP patients in our cohort of 18 HB
cases. Their tumors are characterized by a comparable nuclear stain-
ing for both antibodies and wild-type exon 3 sequence. In fact, the
IHC analysis by itself can already select a large proportion of HBs that
carry an activating CTNNB1mutation, and thus have no increased risk
of an underlying APC germline mutation. Our epitope and immuno-
histochemical analysis suggests that all amino acid alterations and
genomic deletions encompassing the G34-T41 region would prevent
or strongly reduce binding of the S33/37/T41 antibody. Reviewing the
literature for the type of CTNNB1 mutations reported in HBs, it was
found that about 85%ofmutations (198/234) fulfill this criterion.13–21
The main exceptions are D32/S33 amino acid alterations, while S45
mutations are rarely observed in HB (3/234). Although the IHC anal-
ysis can already identifymost HB patients withCTNNB1mutations, we
nevertheless propose to also include the exon 3 mutation analysis on
tumor DNA. This will identify point mutations outside the epitope of
the S33/37/T41 antibody (D32, S33, and S45), and provides a confir-
mation of the CTNNB1mutational status.
As CTNNB1 mutations are the predominant mutation in pediatric
liver cancers (up to 80%), most patients are unlikely carriers of a
germlineAPCmutation. A small subset of cancers ariseswithout appar-
ent 𝛽-catenin activation, that is, the ones with exclusively membra-
nous 𝛽-catenin staining and wild-type sequence. As it is highly unlikely
that such a 𝛽-catenin nuclear-negative tumor arises in a FAP patient,
these are also unlikely to carry a germline APCmutation. Anecdotally,
somatic APC and AXIN1/AXIN2 mutations have been reported in HBs
that also lead to tumors in which wild-type 𝛽-catenin accumulates in
the nucleus.15,16,22 These rare tumorswould lead toAPC germline neg-
ative patients, whereas the tumor analysis indicates an underlying FAP
syndrome. In the next section, we discuss how to deal with this small
subset of HB tumors.
Howcanourmethodbe implemented in current clinical practice?As
HBs can be a manifestation of several genetic syndromes, all patients
should be offered genetic counseling and evaluated for syndromic fea-
tures such as themacrosomia and organomegaly associatedwith BWS.
In the absence of such features and a negative family history, a genetic
mutation analysis is warranted. This should include at least the APC
gene, but may also include other genetic cancer predisposition syn-
dromes such as LFS and NF1.42,43 Simultaneous with or preceding
the counseling process, we propose to combine a routine histopatho-
logical evaluation of the tumor tissue with both 𝛽-catenin stainings
described here. In addition, tumor DNA should be isolated from the
FFPE-material and evaluated for CTNNB1 exon 3mutations, which can
also be done as part of a larger next-generation sequencing panel.
In most cases, the genetic and tumor tissue analyses will cor-
roborate each other. Identification of a germline APC mutation will
be accompanied by a comparable staining with both antibodies and
wild-type CTNNB1 sequence in the tumor tissue, while APC germline
negative cases will show somatic activating CTNNB1 mutations and
reduced staining with the S33/37/T41 antibody. However, given the
approximate 10–20% false-negative APCmutation analyses, occasion-
ally tumors will be identified showing nuclear accumulation of wild-
type 𝛽-cateninwithout an identifiableAPC germlinemutation. As these
cases are at increased risk to develop FAP at a later stage, colono-
scopies of the index patient and its parents can be performed, as
suggested by Aretz et al.2 Using our diagnostic method, this can how-
ever be restricted to the subset of APC germline negative patients that
express wild-type 𝛽-catenin in the tumor. Alternatively, the somatic
mutation analysis of these tumors can be extended to identify inacti-
vating somaticAXIN1/2orAPCmutations;whenAXIN1orAXIN2muta-
tions are identified, this also excludes the diagnosis FAP. In the case of a
“somatic” APCmutation, more caution is needed as this may indicate a
missed germline mutation that is present, for example in a low-mosaic
fashion in the patient.
Our approach can also be extended to other extracolonic FAPman-
ifestations, such as pilomatricomas and desmoids. These lesions are
also characterized by high frequencies of somatic 𝛽-cateninmutations,
meaning that most are of sporadic nature.44–50 About one-third of
CTNNB1 mutations reported for desmoids are at codon S45, and are
missed by the IHC method described here, but—if desired—this anal-
ysis can be extended by including an antibody specifically recognizing
this epitope (e.g. #19807, Cell Signaling technology).
In conclusion, we have successfully established and validated a
novel ß-catenin genetic and immunohistochemical diagnostic method,
which—following confirmation in an independent series—allows the
near-complete exclusion of the diagnosis of FAP among HB patients,
when combinedwith routine germline DNA testing.
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